A Study of Safety and Immunogenicity of a Malaria Vaccine Candidate

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2006
Shanghai Wanxing Bio-Pharmaceuticals is currently evaluating one malaria vaccine candidate, PfCP2.9 adjuvanted with Montanide ISA 720. This trial is designed to test the safety and immunogenicity of 3 doses and 2 vaccination schedules. This blood stage candidate malaria vaccine is being developed for the routine immunization of infants and children living in malaria-endemic areas.
Epistemonikos ID: f09d172b82e8d9d6bcf61e135f0861c810164dfa
First added on: May 04, 2024